Inventiva's Combined Shareholders Meeting of April 16, 2021 -
Availability of the preparatory documents and methods for
participating and voting
Daix (France), March 25, 2021 –
Given the current health context, in accordance with the provisions
of Order no. 2020-321 of March 25, 2020 adapting the form of
meeting and decision-making rules for shareholders meetings and
governing bodies of legal entities during the COVID-19 pandemic, as
prorogated by Decree no. 2021-255 of March 9, 2021, Inventiva
informs its shareholders and the entire financial community of the
decision, taken today by its Chairman and Chief Executive Officer,
upon delegation of the Board of Directors pursuant to Article 7 of
said Order, to hold the next Combined (Ordinary and Extraordinary)
Shareholders Meeting virtually, with no shareholder physically
present, at 2 pm (CET) on April 16, 2021, at the Company’s
registered office.
Availability of the preparatory
documents
Documents for the Shareholders Meeting will be
sent out by email, upon request to the Company, or can be
downloaded from the "Investors" / "Shareholder Meetings" section of
its website at www.inventivapharma.com.
Methods for participating
Shareholders will be able to attend the live
broadcast of the Shareholders Meeting using one of the two
following options:
- Option #1 – Webcast:
https://edge.media-server.com/mmc/p/rdr7tfxe
- Option #2 – Conference call:
Numbers:
France: +33 (0) 1 70 70 07 81Belgium: +32 (0) 2 793 3847Germany:
+49 (0) 69 2222 2625Netherlands: +31 (0) 20 795 6614Switzerland:
+41 (0) 44 580 7145United Kingdom: +44 (0) 207 192 8338United
States: +1 646-741-3167
Access code: 8681244
After the event, a replay of the Shareholders
Meeting will also be available in the "Investors" / "Shareholder
Meetings" section of the Company’s website at
www.inventivapharma.com.
Methods for voting and submitting written
questions
Shareholders are invited to exercise their
voting rights prior to the Shareholders Meeting, either by using
the Internet-based Votaccess secure platform or by sending in their
form-based voting instructions by mail, or by giving proxy. The
proxies to third parties will be processed in accordance with
Article 6 of Decree no. 2020-418 of April 10, 2020.
The detailed modalities for voting are specified
in the notice of the Shareholders Meeting brochure available in the
"Investors" / "Shareholder Meetings" section of the Company’s
website at www.inventivapharma.com and will also be included in the
notice of meeting published in the French Bulletin of Legal
Announcements (BALO).
Since no shareholders will attend the meeting in
person, it will not be possible to ask questions orally during the
Shareholders Meeting. However, in order to encourage dialog,
shareholders will have the opportunity to send their written
questions to the Board of Directors no later than two business days
ahead of the Shareholders Meeting, that is by Wednesday, April 14,
2021. They must be sent to the Company’s registered office by
registered letter with return receipt requested. The questions must
be accompanied by a certificate proving ownership of shares in the
Company’s registered share accounts or in the bearer share accounts
administered by third-party intermediaries, as listed in
Article L. 211-3 of the French Monetary and Financial
Code.
The detailed modalities for submitting written
questions prior to the Shareholders Meeting will also be laid down
in the notice of the Shareholders Meeting, which will be published
in the French Bulletin of Legal Announcements (BALO) and in the
"Investors" / "Shareholder Meetings” section of the Company’s
website at www.inventivapharma.com.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of NASH, MPS and other diseases with significant
unmet medical need.
Leveraging its expertise and experience in the
domain of compounds targeting nuclear receptors, transcription
factors and epigenetic modulation, Inventiva is currently advancing
two clinical candidates, as well as a deep pipeline of earlier
stage programs.
Lanifibranor, its lead product candidate, is
being developed for the treatment of patients with NASH, a common
and progressive chronic liver disease for which there are currently
no approved therapies. In 2020, Inventiva announced positive
topline data from its Phase IIb clinical trial evaluating
lanifibranor for the treatment of patients with NASH and obtained
Breakthrough Therapy and Fast Track designation for lanifibranor in
the treatment of NASH.
Inventiva is also developing odiparcil, a second
clinical stage asset, for the treatment of patients with subtypes
of MPS, a group of rare genetic disorders. Inventiva announced
positive topline data from its Phase IIa clinical trial evaluating
odiparcil for the treatment of adult MPS VI patients at the end of
2019 and received FDA Fast Track designation in MPS VI for
odiparcil in October 2020.
In parallel, Inventiva is in the process of
selecting an oncology development candidate for its Hippo
signalling pathway program. Furthermore, the Company has
established a strategic collaboration with AbbVie in the area of
autoimmune diseases. AbbVie has started the clinical development of
ABBV‑157, a drug candidate for the treatment of moderate to severe
psoriasis resulting from its collaboration with Inventiva. This
collaboration enables Inventiva to receive milestone payments upon
the achievement of pre-clinical, clinical, regulatory and
commercial milestones, in addition to royalties on any approved
products resulting from the collaboration.
The Company has a scientific team of
approximately 70 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, as well as in clinical development. It also owns
an extensive library of approximately 240,000 pharmacologically
relevant molecules, approximately 60% of which are proprietary, as
well as a wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
Inventiva Frédéric Cren Chairman & CEO
info@inventivapharma.com +33 3 80 44 75 00
Brunswick Group Yannick Tetzlaff / Tristan
Roquet Montegon / Aude Lepreux Media relations
inventiva@brunswickgroup.com +33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank Investor relations patti.bank@westwicke.com
+1 415 513 1284
- Inventiva - PR - AGM - Availability of the preparatory
documents - 25 03 2021
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024